Oyster Point Introduces ETF Gene Therapy, First Candidate to Target Neurotrophic Keratopathy
Oyster Point Pharma Inc (NASDAQ:OYST) has announced the expansion of its pipeline with the introduction of Enriched Tear Film (ETF) Gene…
Histogen Stops HST 001 Development After Trial Failure, Shifts Focus On Programs For Orthopedic Indications
Histogen Inc (NASDAQ:HSTO) has decided to suspend the development of the HST 001 program after taking into consideration the results from…
Monopar, National University of Singapore Team Up For Preclinical Assessment Of MNPR-202 In Cancer Settings
Monopar Therapeutics Inc (NASDAQ:MNPR) collaborates with the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs…
CAN-FITE AHEAD OF SCHEDULE IN ITS FIGHT TO TREAT NASH AND LESSEN THE NEED FOR LIVER TRANSPLANTS
Nonalcoholic steatohepatitis (NASH) is the leading cause of disease leading to liver transplants among women and the second-leading cause for liver transplants overall. In addition, NASH is expected to become the leading indicator for liver transplants in men.
Auris Medical Enters RNA Therapeutics with Trasir Therapeutics Acquisition; Plans To Spin-Off/Divest Existing Programs
Auris Medical Holding Ltd (NASDAQ:EARS) has acquired privately-held Trasir Therapeutics Inc, focused on extrahepatic oligonucleotide delivery. The purchase price comprises 0.77…
Medtronic Halts Sale of Heart Device HVAD System Over Neurological Adverse Events
Medtronic plc (NYSE:MDT) will stop the distribution and sale of its HVAD System and has notified physicians to cease new implants…
Edesa Biotech’s EB01 Shows Encouraging Interim Results In Dermatitis Trial
Edesa Biotech Inc’s (NASDAQ:EDSA) EB01 has met a key interim study parameter as part of an adaptive Phase 2b trial evaluating EB01 as…
VBL Therapeutics Stock Jumps on Adding PFS as Second Independent Primary Endpoint in Ovarian Cancer Gene Therapy Trial
VBL Therapeutics Ltd (NASDAQ:VBLT) has amended the primary endpoint in the OVAL Phase 3 registration-enabling study of VB-111 (ofranergene obadenovec) gene therapy for…
Tonix Pharma Fibromyalgia Treatment Associated with Improvement in Pain, Sleep, Fatigue
Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) has announced the poster presentation of previously reported results from its Phase 3 RELIEF trial evaluating the TNX-102…
Updated Analysis Show Seagen’s Tukysa Extended Median OS to Two Years with Benefits Maintained in Breast Cancer
Seagen Inc (NASDAQ:SGEN) has announced that improvements in overall survival (OS) and progression-free survival (PFS) were maintained with long-term follow-up from…